Martin D. Madaus, Director at REPLIGEN CORP (RGEN), bought 1,800 shares at $112.13 ($202K) on 2025-08-08, disclosed to the SEC on 2025-08-12.
Open-market purchase of $202k RGEN by Director. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history). Context: insider career grade C.
Nothing distinguishes this filing.
| Filing → |
| RGEN | BUY | 2024-06-14 | $316K | — | Filing → |
| RGEN | BUY | 2023-05-08 | $238K | — | Filing → |
| QTRX | BUY | 2022-08-10 | $1.5M | — | Filing → |